MLAB - Mesa Laboratories, Inc.
269.70 0.00 (0.00%)
After hours: 4:00PM EST
| Previous Close | 267.70 |
| Open | 267.00 |
| Bid | 269.28 x 800 |
| Ask | 270.28 x 800 |
| Day's Range | 266.18 - 270.21 |
| 52 Week Range | 181.21 - 271.11 |
| Volume | 26,222 |
| Avg. Volume | 38,421 |
| Market Cap | 1.188B |
| Beta (5Y Monthly) | 0.25 |
| PE Ratio (TTM) | 261.59 |
| EPS (TTM) | 1.03 |
| Earnings Date | Feb 09, 2020 |
| Forward Dividend & Yield | 0.64 (0.24%) |
| Ex-Dividend Date | Feb 26, 2020 |
| 1y Target Est | 273.75 |
- GlobeNewswire
Mesa Labs Reports Third Quarter Results
LAKEWOOD, Colo., Feb. 10, 2020 -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, or “Mesa Labs”) today reported third quarter results for the three months ended December.
- Simply Wall St.
Why We’re Not Keen On Mesa Laboratories, Inc.’s (NASDAQ:MLAB) 5.0% Return On Capital
Today we are going to look at Mesa Laboratories, Inc. (NASDAQ:MLAB) to see whether it might be an attractive...
- Zacks
Mesa Labs (MLAB) Earnings Expected to Grow: Should You Buy?
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
MESA LABS DECLARES QUARTERLY DIVIDEND
LAKEWOOD, Colo., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. Mesa is a global technology innovator committed to solving some of the most critical quality control challenges in the pharmaceutical, healthcare, industrial safety, environmental and food and beverage industries. Mesa offers products and services through five divisions (Sterilization and Disinfection Control, Biopharmaceutical Development, Instruments, Cold Chain Monitoring and Cold Chain Packaging) to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.
- Insider Monkey
Is Mesa Laboratories, Inc. (MLAB) A Good Stock To Buy ?
The market has been volatile in the last few months as the Federal Reserve finalized its rate cuts and uncertainty looms over trade negotiations with China. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by more than 10 percentage […]
- Zacks
Mesa Labs (MLAB) Q2 Earnings Top Estimates
Mesa Labs (MLAB) delivered earnings and revenue surprises of 0.58% and -1.79%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Mesa Labs Reports Record Second Quarter Revenues and Adjusted Operating Income
LAKEWOOD, Colo., Nov. 06, 2019 -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today reported record second quarter revenues and adjusted.
- GlobeNewswire
Mesa Labs Acquires Gyros Protein Technologies
LAKEWOOD, Colo., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (MLAB) (we, us, our, “Mesa” or the “Company”), a diversified supplier of quality control instruments and consumables to highly regulated markets today announced the acquisition of Gyros Protein Technologies Holding AB (“GPT”). GPT is headquartered in Uppsala, Sweden and is a leading provider of Immunoassay and Peptide Synthesis solutions that accelerate the discovery, development and manufacturing of biotherapeutics. The acquisition deepens our commitment to biopharmaceutical quality control and will be the core of our new platform, Biopharmaceutical Development.
- Insider Monkey
Hedge Funds Are Dumping Mesa Laboratories, Inc. (MLAB)
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
- Zacks
Mesa Labs (MLAB) Earnings Expected to Grow: What to Know Ahead of Q2 Release
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
The Mesa Laboratories (NASDAQ:MLAB) Share Price Is Up 205% And Shareholders Are Boasting About It
It might be of some concern to shareholders to see the Mesa Laboratories, Inc. (NASDAQ:MLAB) share price down 15% in...
- Simply Wall St.
Mesa Laboratories (NASDAQ:MLAB) Seems To Use Debt Quite Sensibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- GlobeNewswire
Mesa Laboratories, Inc. Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes
Mesa Laboratories, Inc. (MLAB) (“Mesa”) today announced the pricing of concurrent underwritten public offerings of (a) 375,000 shares of its common stock at a public offering price of $210.00 per share for gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, of approximately $78.8 million and (b) $150 million aggregate principal amount of its 1.375% convertible senior notes due 2025 (the “notes”). In addition, Mesa has granted (a) the underwriters of the common stock offering a 30-day option to purchase up to 56,250 additional shares and (b) the underwriters of the notes offering a 13-day option to purchase up to $22.5 million aggregate principal amount of additional notes. The offering of the shares is expected to result in approximately $73.9 million in net proceeds to Mesa after deducting underwriting discounts and commissions and other estimated offering expenses payable by Mesa (assuming no exercise of the underwriters’ option to purchase additional shares).
- GlobeNewswire
Mesa Laboratories, Inc. Announces Proposed Public Offering of Common Stock and Convertible Senior Notes
Mesa Laboratories, Inc. (MLAB) (“Mesa”) today announced that it has commenced concurrent underwritten public offerings of 375,000 shares of its common stock and $150 million aggregate principal amount of its convertible senior notes due 2025 (the “notes”). In addition, Mesa expects to grant (a) the underwriters of the common stock offering a 30-day option to purchase up to 56,250 additional shares and (b) the underwriters of the notes offering a 13-day option to purchase up to $22.5 million aggregate principal amount of additional notes.
- Simply Wall St.
Is Mesa Laboratories, Inc.'s (NASDAQ:MLAB) 6.6% ROE Worse Than Average?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
- Zacks
Mesa Labs (MLAB) Beats Q1 Earnings and Revenue Estimates
Mesa Labs (MLAB) delivered earnings and revenue surprises of 7.18% and 2.29%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Mesa Labs Reports Record First Quarter Revenues and Adjusted Operating Income
LAKEWOOD, Colo., July 30, 2019 -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today reported record first quarter revenues and adjusted.
- Zacks
Earnings Preview: Mesa Labs (MLAB) Q1 Earnings Expected to Decline
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Insider Monkey
Hedge Funds Have Never Been More Bullish On Mesa Laboratories, Inc. (MLAB)
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of March. At Insider Monkey, we follow nearly 750 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]
- PR Newswire
MarketAxess Holdings Set to Join S&P 500; Axon Enterprise to Join S&P MidCap 400; Others to Join S&P SmallCap 600
NEW YORK , June 24, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: S&P MidCap 400 constituent MarketAxess Holdings Inc. ...
- Simply Wall St.
Why You Should Like Mesa Laboratories, Inc.’s (NASDAQ:MLAB) ROCE
Today we'll look at Mesa Laboratories, Inc. (NASDAQ:MLAB) and reflect on its potential as an investment. Specifically...
- Associated Press
Mesa Labs: Fiscal 4Q Earnings Snapshot
The Lakewood, Colorado-based company said it had net income of 34 cents per share. Earnings, adjusted for stock option expense and amortization costs, were $1.75 per share. The quality control instruments ...
- GlobeNewswire
Mesa Labs Reports Record Revenues and Adjusted Operating Income for Fiscal Year 2019
LAKEWOOD, Colo., June 03, 2019 -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today reported record revenues and adjusted operating income1 for.
